SM-88, a novel compound that attacks oncogenic metabolic pathways, is under development for patients with metastatic pancreaticcancer and other solid tumors, raising the potential for a tumor-agnostic therapy.
More From BioPortfolio on "Novel Metabolic Therapy Demonstrates Activity in Metastatic Pancreatic Cancer"